Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)
Pavlidis, Nicholas ; Aamdal, Steinar ; Awada, Ahmad ; Calvert, Hilary ; Fumoleau, Pierre ; Sorio, Roberto ; Punt, Cees ; Verweij, Jaap ; van Oosterom, Allan ; Morant, Rudolf ; Wanders, Jantien ; Hanauske, Axel-R.
Springer
Published 2000
Springer
Published 2000
| ISSN: |
1432-0843
|
|---|---|
| Keywords: |
Key words Carzelesin ; Lymphoma ; Solid tumors ; Toxicity
|
| Source: |
Springer Online Journal Archives 1860-2000
|
| Topics: |
Medicine
|
| Notes: |
Abstract Purpose: In a phase II trial, the activity of carzelesin, a cyclopropylpyrroloindole prodrug analog, was assessed. Patients and methods: Carzelesin was used as second- or third-line chemotherapy in patients with breast, ovarian, head and neck cancer and non-Hodgkin's lymphoma, and as first-line chemotherapy in patients with colorectal and gastric cancer and melanoma. The drug was given as a bolus infusion at a 4-weekly dose of 150 μg/m2. A total of 140 patients were entered and a total of 285 courses were administered. Results: In general, the compound was well tolerated. Myelotoxicity was the most common toxicity. Grade 3 and 4 leukopenia was observed in 18.6% of the courses, neutropenia in 20.3%, thrombocytopenia in 16.2% and anemia in 8.7%. Double nadirs were seen in a total of 41 courses for neutrophils, in 40 for leukocytes and in 3 for platelets. Non-hematological toxicity was very mild. Only one partial response in a patient with melanoma was seen. Conclusions: At this dose and schedule carzelesin did not yield activity in the types of tumors studied.
|
| Type of Medium: |
Electronic Resource
|
| URL: |